What's new

EMEA-003522-PIP01-23

EMEA-003522-PIP01-23

Apr 1, 2025 - 15:37
 0
EMEA-003522-PIP01-23
EMEA-003522-PIP01-23
Read More

Tags:

Previous Article

Biopharmas laid off staffers at least 63 times in Q1: Fierce Biotech analysis

Next Article

EDPR NA powers 100MW solar PV plant in Indiana, inks PPA with Amazon

Related Posts

Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 17, 2025  0

EU Innovation Network (EU-IN)

EU Innovation Network (EU-IN)

Feb 13, 2025  0